<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425434</url>
  </required_header>
  <id_info>
    <org_study_id>GFAOP RB1</org_study_id>
    <nct_id>NCT04425434</nct_id>
  </id_info>
  <brief_title>Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma</brief_title>
  <acronym>GFARB12019</acronym>
  <official_title>Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Africa Pediatric Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Africa Pediatric Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the survival of children with retinoblastoma in high income countries is higher than 95%
      including the bilateral forms this study hopes to improve the outcome in low income countries
      in Africa by improving early diagnosis and early implementation of this protocol of
      therapeutic recommendations for treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we will try to improve the outcome for children with stage II disease. It is
      hoped that we will be able to show that with early intervention correct early diagnosis the
      survival of these children is greatly improved. The collection of data in this observational
      study will allow us to show this improvement, by analysis of stage, treatment and outcome.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">October 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cases with retinoblastoma in each participating hospital.</measure>
    <time_frame>10 years</time_frame>
    <description>Evaluation of the number of cases registered .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of cases with stage 2 disease</measure>
    <time_frame>10 years</time_frame>
    <description>Evaluation of the number of cases registered with stage 2 disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of these therapeutic recommendations in an African setting</measure>
    <time_frame>10 years</time_frame>
    <description>Evaluate the application of these therapeutic recommendations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating the treatment given.</measure>
    <time_frame>10 years</time_frame>
    <description>Comparison of treatment given and recommended treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>follow up</measure>
    <time_frame>10 years</time_frame>
    <description>analysis of the number of children alive or dead after treatment</description>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Retinoblastoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OBSERVATIONAL</intervention_name>
    <description>We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all children presenting at participating units who can be treated
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral intraocular Retinoblastoma (RB)

          -  Unilateral extraocular intraorbital (RB)

          -  Bilateral intraocular (RB)

          -  bilateral intraocular (RB) on one side and extraocular but intraorbital on the other
             side.

        Exclusion Criteria:

          -  Externalized tumor mass

          -  massive extension to optic nerve up to optical channeltumor

          -  intracranial extension leptomeninges

          -  cerebral parenchyma

          -  extension to regional lymph nodes and/or remote metastases.

          -  cerebrospinal fluid involvement.

          -  Trilateral RB

          -  Incapacity to followed the whole treatement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>FOUSSEYNI Mr TRAORE, Dr;</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMCC AND GFAOP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KARIM Mr ASSANI, Dr.</last_name>
    <phone>00243971359726</phone>
    <email>drassanik@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BRENDA Ms MALLON, MSc</last_name>
    <phone>0033142115411</phone>
    <email>brenda.mallon@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Treichville à ABIDJAN</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

